Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Several weeks ago, we were fortunate enough to have Dr. Mary Pinder (alternately referred to as Pinder-Schenck) from the H. Lee Moffitt Cancer Center in Tampa join as the first of two speakers reviewing highlights in thoracic oncology from ASCO. She covered several key presentations in small cell lung cancer, early stage non-small cell lung cancer, and mesothelioma. Here's the audio and video versions of the podcast, along with the transcript and figures (a zip file to decompress, since it was too big in unzipped form to upload) for this program:
[powerpress]
pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-audio-podcast
pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-transcript
pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-figures
This program will be followed by Dr. Nasser Hanna's presentation of the highlights from advanced NSCLC at ASCO 2011, and then question and answer time as an additional podcast. The live webinar, as well as all of these podcasts, were developed in partnership with LUNGevity Foundation. We're very grateful for their support.
And for those of you reminded of how much you like Dr. Pinder, don't worry -- she's coming back for September.
Please feel free to offer comments and raise questions in our
discussion forums.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.